BioCentury | Jan 6, 2017
Finance

Tiers of disappointment

...Momelotinib fails in the Phase III SIMPLIFY-2 trial to treat myelofibrosis Horizon Pharma plc (NASDAQ:HZNP) Actimmune...
BioCentury | Dec 14, 2016
Clinical News

Actimmune: Ph III STEADFAST data

...Horizon discontinued development of Actimmune to treat Friedreich's ataxia after top-line data from the double-blind, U.S...
...from the double-blind, U.S. Phase III STEADFAST trial in 92 patients showed that thrice-weekly subcutaneous Actimmune...
...missed the primary endpoint of improving FARS-mNeuro score from baseline to week 26 vs. placebo. Actimmune...
BioCentury | Dec 9, 2016
Clinical News

Horizon dips on Phase III Friedreich's ataxia miss

...Horizon Pharma plc (NASDAQ:HZNP) dropped $4.36 (22%) to $15.03 on Thursday after it said Actimmune interferon...
...The company said it will discontinue the candidate's development in the indication. Compared to placebo, Actimmune...
...trial enrolled 92 patients and was conducted by Horizon and the Friedrich's Ataxia Research Alliance. Actimmune...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...NASDAQ:HRTX) HTX-019 Prevent chemotherapy-induced nausea and vomiting (CINV) Submit NDA 2H16 Horizon Pharma plc (NASDAQ:HZNP) Actimmune...
BioCentury | May 30, 2016
Company News

Boehringer Ingelheim, Horizon Pharma deal

...to treat chronic granulomatous disease (CGD) and severe, malignant osteoporosis. Horizon markets the drug as Actimmune...
BioCentury | May 16, 2016
Clinical News

Actimmune interferon gamma-1b: Completed Phase III enrollment

...enrollment of 90 patients in the double-blind, placebo-controlled, U.S. Phase III STEADFAST trial evaluating subcutaneous Actimmune...
...thrice weekly for 26 weeks. Patients will receive an initial dose of 10 ug/m 2 Actimmune...
...who complete the trial are eligible to continue treatment in a 26-week, open-label extension study. Actimmune...
BioCentury | May 7, 2016
Financial News

ACT Genomics raises $12.5M series B

...Genomics markets ACTDrug and ACTOnco, diagnostics that pinpoint genomic alterations linked to cancer, and the ACTImmune...
BioCentury | Jan 11, 2016
Finance

Sowing season

...aprepitant (HTX-019) Chemotherapy induced nausea and vomiting (CINV) Submit NDA 2H16 Horizon Pharma plc (NASDAQ:HZNP) Actimmune...
BioCentury | Jan 4, 2016
Clinical News

Actimmune interferon gamma-1b: Phase I started

...Horizon began an open-label, U.S. Phase I trial to evaluate subcutaneous Actimmune every other day in...
...with advanced solid tumors who have progressed on >=1 prior systemic therapy. Patients will receive Actimmune...
...50 ug/m 2 for the first week, followed by Opdivo given every 2 weeks and Actimmune...
BioCentury | Sep 14, 2015
Company News

Fox Chase Cancer Center, Horizon Pharma deal

...Horizon and Fox Chase partnered to study Horizon’s Actimmune with PD-1 / PD-L1 inhibitors in cancer...
...The study will then be expanded to patients with metastatic bladder and renal cell carcinomas. Actimmune...
Items per page:
1 - 10 of 245